Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes

Pediatric Diabetes

Volumn 13, Issue 1, 2012, Pages 51-58

  Kaas, Anne ^a   Max Andersen, Marie Louise ^a   Fredheim, Siri ^a   Hougaard, Philip ^b   Buschard, Karsten ^c   Petersen, Jacob Steen ^d   de Beaufort, Carine ^e,h   Robertson, Kenneth J ^f   Hansen, Lars ^a   Mortensen, Henrik B ^a,r   Nielsen, Lotte B ^a   Aanstoot, Henk Jan ^g   Chiarelli, Francesco ⁱ   Dahl Jørgensen, Knut ^j   Göthner, Hilde Bjørndalen ^j   Danne, Thomas ^k   Garandeau, Patrick ^l   Greene, Stephen A ^m   Holl, Reinhard W ⁿ   Kocova, Mirjana ^o   Martul, Pedro ^p   Matsuura, Nobuo ^q   Schoenle, Eugen J ^s   Swift, Peter ^t   Tsou, Rosa Maria ^u   Vanelli, Maurizio ^v   Åman, Jan ^w   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d NOVO NORDISK A S   (Denmark)

^e CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^f ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h Clinique Pediatrique   (Luxembourg)

ⁱ Clinica Pediatrica   (Italy)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l Institut Saint Pierre   (France)

^m UNIVERSITY OF DUNDEE   (United Kingdom)

ⁿ UNIVERSITY OF ULM   (Germany)

^o Pediatric Clinic Skopje   (Macedonia)

^p HOSPITAL DE CRUCES   (Spain)

^q KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^s UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^t LEICESTER ROYAL INFIRMARY   (United Kingdom)

^u Paediatric Department Oporto   (Portugal)

^v UNIVERSITY OF PARMA   (Italy)

^w ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

more..

Author keywords

GLP 1; Glucagon; Proinsulin; Remission phase; Type 1 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN ANTIBODY; INSULIN DOSE ADJUSTED HBA1C; PROINSULIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CELL FUNCTION; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PARTIAL REMISSION; PRIORITY JOURNAL; REMISSION; TEST MEAL;

ADOLESCENT; AGE OF ONSET; BLOOD GLUCOSE; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROINSULIN; REMISSION, SPONTANEOUS;

EID: 84856405133     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2011.00812.x     Document Type: Article

References (31)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001: 358: 221-229.
2. Klimek AM, Soukhatcheva G, Thompson DM et al. Impaired proinsulin processing is a characteristic of transplanted islets. Am J Transplant 2009: 9: 2119-2125.
3. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997: 46: 1725-1732.
4. Porte D Jr, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes 1989: 38: 1333-1336.
5. Leahy JL, Halban PA, Weir GC. Relative hypersecretion of proinsulin in rat model of NIDDM. Diabetes 1991: 40: 985-989.
6. Roder ME, Porte D Jr, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998: 83: 604-608.
7. Spinas GA, Snorgaard O, Hartling SG, Oberholzer M, Berger W. Elevated proinsulin levels related to islet cell antibodies in first-degree relatives of IDDM patients. Diabetes Care 1992: 15: 632-637.
8. Hostens K, Pavlovic D, Zambre Y et al. Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release. J Clin Invest 1999: 104: 67-72.
9. Ludvigsson J, Heding L. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabetol Lat 1982: 19: 351-358.
10. Snorgaard O, Kjems LL, Roder ME, Hartling SG, Dinesen B, Binder C. Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies. Diabetes Care 1996: 19: 146-150.
11. Mortensen HB, Swift PG, Holl RW et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010: 11: 218-226.
12. Scholin A, Nystrom L, Arnqvist H et al. Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults. Diabet Med 2011: 28: 156-161.
13. Bohmer K, Keilacker H, Kuglin B et al. Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies. Diabetologia 1991: 34: 830-834.
14. Kawamori D, Kulkarni RN. Insulin modulation of glucagon secretion: the role of insulin and other factors in the regulation of glucagon secretion. Islets 2009: 1: 276-279.
15. Muller WA, Faloona GR, Unger RH. The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest 1971: 50: 1992-1999.
16. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996: 19: 580-586.
17. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006: 49: 253-260.
18. Kaas A, Pfleger C, Hansen L et al. Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis. Clin Exp Immunol 2010: 161: 444-452.
19. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982: 207: 381-388.
20. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994: 43: 535-539.
21. Porksen S, Nielsen LB, Kaas A et al. Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab 2007: 92: 2910-2916.
22. Mortensen HB, Hougaard P, Swift P et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009: 32: 1384-1390.
23. Dromey JA, Lee BH, Yu H et al. Generation and expansion of regulatory human CD4(+) T-cell clones specific for pancreatic islet autoantigens. J Autoimmun 2011: 36: 47-55.
24. Arai T, Moriyama H, Shimizu M et al. Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice. Clin Immunol 2010: 136: 74-82.
25. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987: 65: 30-36.
26. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1. J Mol Endocrinol 2008: 41: 35-44.
27. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011: 13: 394-407.
28. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011: 13: 542-550.
29. Pratley RE, Schweizer A, Rosenstock J et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008: 10: 931-938.
30. Bosi E. Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab 2010: 95: 2607-2609.
31. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009: 5: 266-275.